Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Case Review: Small Cell Lung Cancer Following LEMS

January 11th 2022

An oncologist reviews the case of a 57-year-old man diagnosed with small cell lung cancer after Lambert-Eaton myasthenic syndrome.

Monitoring Patients with SCLC and LEMS

January 11th 2022

Drs. Steven Vernino and David Gerber continue their conversation on their preferred treatment approaches and monitoring strategies for Lambert-Eaton myasthenic syndrome and small cell lung cancer.

Dr. Iams on Establishing the Clinical Utility of ctDNA Testing in Lung Cancer

January 10th 2022

Wade T. Iams, MD, discusses the need to establish the clinical utility of circulating tumor DNA testing in lung cancer.

NSCLC Paradigm Progresses With Adjuvant Treatment and Overcoming Resistance

January 10th 2022

As the armamentarium of advanced non–small cell lung cancer () continues to grow with the addition of novel targeted therapies for rare patient subtypes, the field is simultaneously shifting to evaluate targeted therapy and immunotherapy in earlier lines of treatment, including the neoadjuvant and adjuvant spaces.

Sotorasib Approved in Europe for KRAS G12C–Mutated Advanced NSCLC

January 10th 2022

The European Commission has granted conditional marketing authorization to sotorasib for the treatment of adult patients with KRAS G12C mutant advanced non–small cell lung cancer.

Adjuvant Pembrolizumab Improves DFS in Stage IB-IIIA NSCLC, Irrespective of PD-L1 Expression

January 10th 2022

Adjuvant treatment with pembrolizumab led to a statistically significant and clinically meaningful improvement in disease-free survival vs placebo in patients with stage IB to IIIA non–small cell lung cancer following resection, regardless of PD-L1 expression, meeting 1 of the dual primary end points of the phase 3 KEYNOTE-091 trial.

Future Outlook of EGFR Mutant NSCLC

January 10th 2022

Solange Peters, MD, PhD, and Tony SK Mok, MD, discuss what they’re looking forward to in the future for treating both stages of EGFR mutant NSCLC and give advice to colleagues treating this disease.

Updates in the Treatment of EGFR Mutant Advanced-Stage NSCLC

January 10th 2022

Drs Mok and Peters explain the updates seen in the treatment landscape for EGFR mutant advanced-stage NSCLC.

Immunotherapy Continues to Touch All Areas of Lung Cancer Treatment

January 9th 2022

David Spigel, MD, discussed the focus of each presentation, which centered on immunotherapy vs chemoimmunotherapy in the frontline metastatic setting, the surgical perspective of treatment in early-stage NSCLC, best practices for molecular testing, and EGFR- and KRAS-targeted therapies for patients with advanced disease.

Johnson Drives Home the Importance of Biomarker Testing in Lung Cancer

January 8th 2022

One of the reverberating themes of 2021 that should carry into 2022 is the importance of molecular testing.

Biomarkers for Guiding Treatment in NSCLC: Liquid Biopsy Versus Tissue-Based Testing

January 7th 2022

A comprehensive discussion on the value and limitations of tissue-based versus liquid-based biomarker testing in non–small cell lung cancer.

CLN-081 Continues to Elicit Encouraging, Durable Responses in EGFR Exon 20 Insertion+ NSCLC

January 6th 2022

CLN-081 continued to produce encouraging, durable responses with favorable safety and tolerability in patients with non–small cell lung cancer whose tumors harbor EGFR exon 20 insertion mutations and who have progressed on or after prior therapy.

A Gut Check on the Digital Divide: How Wearable Devices Are Changing Cancer Care

January 6th 2022

The idea to provide wearable devices to my patients first came to me 6 years ago at a charity spinning event.

Mirati and Verastem Combine to Address Unmet Need in KRAS G12C–Mutant NSCLC

January 5th 2022

Mirati Therapeutics and Verastem Oncology have entered a nonexclusive clinical collaboration to evaluate the combination of adagrasib plus VS-6766 for patients with non–small cell lung cancer harboring a KRAS G12C mutation who have progressed on a KRAS G12C inhibitor in a phase 1/2 trial.

Telisotuzumab Vedotin Receives Breakthrough Therapy Status From FDA for Select NSCLC

January 5th 2022

The FDA granted a breakthrough therapy designation to telisotuzumab vedotin for use in patients with advanced or metastatic EGFR wild-type, nonsquamous non–small cell lung cancer who have high levels of c-Met overexpression and whose disease has progressed on, or after, platinum-based chemotherapy.

Predominant Lung Cancer Investigator Welcomes a New Era of Research

January 5th 2022

Early efficacy data in a phase 1 trial of the agent now known as nivolumab were not enough to convince Julie Brahmer, MD, MSc, about the potential of the investigative agent.

Tiragolumab Plus Atezolizumab Demonstrates Improvement in PFS, OS, ORR in PD-L1+ NSCLC

January 4th 2022

The addition of tiragolumab to atezolizumab produced a clinically meaningful improvement in progression-free survival, overall survival, and objective response rate compared with atezolizumab alone in the first-line treatment of patients with PD-L1–positive non–small cell lung cancer.

CLN-081 Granted FDA Breakthrough Therapy Designation Status for EGFR-Mutated NSCLC

January 4th 2022

The FDA has granted breakthrough therapy designation to CLN-081 for the treatment of patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations and who have received prior platinum-based chemotherapy.

How Has Biomarker Testing Impacted Clinical Practice Across Geographic Regions?

January 4th 2022

A broad review on how biomarker testing has impacted the clinical staging and management of non–small cell lung cancer across geographic regions.

Treatment Options for LEMS

January 4th 2022

Key opinion leaders detail the treatment options available for Lambert-Eaton myasthenic syndrome.